ABSTRACT
ABSTRACT Objective: Tyrosinemia type III (HT III) is the rarest form of tyrosinemia, and the full clinical spectrum of this disorder is still unknown. The neurological involvement varies, including intellectual impairment and attention deficit disorder with hyperactivity (ADHD). We report the case of two siblings diagnosed with HT III at different ages. Case description: The index case was diagnosed by newborn screening for endocrine and metabolic disorders, starting a low-protein diet immediately, with a consistent decrease in tyrosine levels. By the age of three, the child displayed a hyperactive behavior, starting treatment for ADHD two years later. At seven years of age, he shows a slight improvement in terms of behavior and attention span and has a cognitive performance slightly lower than his peers, despite maintaining acceptable tyrosine levels. His sister, who had a history of ADHD since age five, was diagnosed with HT III after family screening at the age of eight. Despite initiating a dietetic treatment, her behavior did not improve, and she has a mild intellectual impairment. Comments: This is the first case report describing siblings with HT III who underwent nutritional treatment with a low-protein diet in different phases of life, with a better neurological and behavioral evaluation in the patient who started treatment earlier.
RESUMO Objetivo: A tirosinemia tipo III (TT III) é a forma mais rara das tirosinemias e o espectro clínico desta entidade não está totalmente esclarecido. O envolvimento neurológico é variável, incluindo o atraso cognitivo ou transtorno do déficit de atenção com hiperatividade (TDAH). Descrevemos o caso de dois irmãos que foram diagnosticados com TT III em idades diferentes. Descrição dos casos: O caso índice foi diagnosticado no contexto do rastreio endócrino-metabólico neonatal, tendo iniciado imediatamente dieta hipoproteica, com redução consistente dos níveis de tirosina. Por volta dos três anos, foi detectado um comportamento hiperativo, tendo iniciado dois anos depois tratamento para o TDAH. Aos sete anos, apresenta leve melhora de comportamento e da atenção e avaliação cognitiva levemente inferior ou pouco abaixo quando comparado a crianças da mesma faixa etária, apesar de manter níveis aceitáveis de tirosina. A sua irmã, com história de TDAH desde os cinco anos, foi diagnosticada de TT III aos oito anos no contexto do rastreio de familiares. Apesar de iniciar tratamento dietético, nenhum efeito foi notado em termos de comportamento e a doente apresenta leve atraso cognitivo. Comentários: Este é o primeiro caso clínico descrito de irmãos com TT III que iniciaram terapêutica dietética com dieta hipoproteica em diferentes fases da vida, com melhor avaliação em termos neurológicos e comportamentais no doente que iniciou tratamento mais precocemente.
Subject(s)
Humans , Male , Female , Infant, Newborn , Infant , Child, Preschool , Child , Attention Deficit Disorder with Hyperactivity/etiology , Tyrosinemias/diagnosis , Tyrosinemias/complications , Tyrosinemias/therapy , SiblingsABSTRACT
Se describe el caso clínico de una paciente de 2 meses de edad, quien nació a término y normopeso; se alimentaba con lactancia materna exclusiva y tuvo antecedente de 2 ingresos previos (anemia severa y catarro común). Fue hospitalizada en el Servicio de Terapia Intensiva del Hospital Infantil Sur Dr Antonio María Béguez César por presentar edemas generalizados y ascitis, con evolución rápida hacia un cuadro de insuficiencia hepática aguda. Las pruebas metabólicas de orina y sangre permitieron confirmar el diagnóstico de tirosinemia de tipo 1. A pesar de brindarle la atención requerida, la paciente evolucionó desfavorablemente.
The case report of a 2 months of age patient is described who was born at term and normal in weight; she fed with exclusive breast feeding and she had a history of 2 previous admissions (severe anemia and common cold). She was hospitalized in the Intensive Therapy Service of Dr Antonio María Béguez Caesar Southern Pediatric Hospital due to widespread edemas and ascites, with a fast clinical course to an acute liver failure. The metabolic tests of urine and blood allowed to confirm the diagnosis of type 1 tyrosinemia. In spite of offering her the required care, the patient had an unfavourable clinical course.
Subject(s)
Humans , Female , Infant , Tyrosinemias/complications , Steroid Metabolism, Inborn Errors , Intensive Care Units, Pediatric , Amino Acid Metabolism, Inborn ErrorsABSTRACT
Background: Tyrosinemia type I is an inborn error of metabolism due to deficiency of fumarilacetoacetase. Acute presentation is with liver failure, hypophosphatemic rickets and peripheral neuropathy. Chronic presentation is with visceromegaly and subclinical rickets. The most severe complications are hepatic cancer and acute neurological crises. Without treatment, tyrosinemia type 1 is fatal. In 1992 treatment for tyrosinemia type 1 with 2-(2-nitro-4-trifluoromethybenzoyl)-1,3-ciclohexanedione (NTBC) was proposed. A clinical response was reported in 90% of patients. In cases that did not respond, a successful liver transplantation was performed, reducing mortality to 5%. Aim: To report the follow up of 12 patients treated with NTBC. Patients and Methods: Review of clinical records of 12 Chilean cases treated with NTBC at the Instituto de Nutrición y Tecnología de los Alimentos (INTA) from January 2004 until June 2010. Results: In all patients, a rapid metabolic control was achieved. Two patients developed hepatocarcinoma. One of these patients died and one was successfully treated with liver transplantation. One patient died after receiving a liver transplantation. Nine patients have at present good liver function, but 2 had peripheral neuropathy due to late diagnosis and discontinuing NTBC treatment. Conclusions: Treatment with NTBC allows metabolic normalization in tyrosinemia type 1, prevents liver cirrhosis and hepatic cancer, improving survival rates and quality of life in the patients. Neonatal screening is essential for the early diagnosis of this treatable disease, that otherwise may be lethal.
Subject(s)
Child, Preschool , Female , Humans , Infant , Male , Cyclohexanones/therapeutic use , Enzyme Inhibitors/therapeutic use , Nitrobenzoates/therapeutic use , Tyrosinemias/drug therapy , Chile , Follow-Up Studies , Liver Neoplasms/etiology , Liver Neoplasms/prevention & control , Liver Transplantation/adverse effects , Liver Transplantation/mortality , Retrospective Studies , Time Factors , Treatment Outcome , Tyrosinemias/complications , Tyrosinemias/metabolismABSTRACT
Tyrosinemia is a rare paediatric metabolic liver disorder. A 15-days-old neonate born of a third degree consanguineous marriage presented with jaundice due to tyrosinemia, which progressed to fatal hepatic encephalopathy. The diagnosis was based on very high alpha-fetoprotein level, with urine aminoacidogram revealing tyrosine spot and liver biopsy depicting cirrhosis. Very early neonatal presentation and rapid progression were the unusual features of this case.
Subject(s)
Humans , Infant, Newborn , Male , Tyrosinemias/complicationsABSTRACT
Bilateral pseudo-dendritic keratitis in infancy can be due to tyrosinemia, a rare metabolic disorder. Ocular involvement may be the earliest presenting manifestation of this disease. Early diagnosis is essential because dietary modifications can result in complete reversal of the manifestations of this disorder. This disease must be suspected in all cases of non-responsive dendritic keratitis in the pediatric age group, especially if it is associated with cutaneous lesions such as patmoplantar keratosis. Serum tyrosine levels must be done in these cases.
Subject(s)
Diagnosis, Differential , Humans , Infant , Keratitis, Dendritic/diagnosis , Tyrosinemias/complicationsABSTRACT
Richner Hanhart syndrome is a rare inherited disorder involving the metabolism of tyrosine, a semi-essential amino acid and it should be considered in the differential diagnosis of a child presenting with ocular and skin lesions. We report a case of Richner Hanhart syndrome in a 19-month-old child, who presented with ocular and skin lesions.
Subject(s)
Eye Diseases/etiology , Female , Humans , Infant , Skin Diseases/etiology , Tyrosinemias/complicationsABSTRACT
La Tirosinemia tipo I es el resultado de un error innato en la etapa final del metabolismo de la Tirosina. Sus manifestaciones clínicas son variables, las cuales pueden verse agravadas con la aparición de crisis neurológica. El objetivo del presente trabajo es reportar el caso de una preescolar portadora de la enfermedad, que desarrolló parálisis fláccida asociada a insuficiencia respiratoria y que requirió conexión a ventilación mecánica.
Subject(s)
Humans , Female , Child, Preschool , Respiratory Insufficiency/complications , Paralysis/complications , Paralysis/therapy , Respiration, Artificial , Tyrosinemias/complications , Tyrosinemias/diagnosis , Tyrosinemias/diet therapy , Hepatic Insufficiency , Metabolism, Inborn Errors , Muscle Fatigue , Renal Insufficiency , Tyrosine/deficiencyABSTRACT
We present two documented cases of patients with Tyrosinemia type I (Hepatorenal Tyrosinemia) in infants. The most constant imaging findings in target organs: Liver (Hepatic Cirrhosis), Kidneys (Nefromegaly) are described and compared with pathological findings in one case. In the presence of confusing clinical manifestations, radiological findings of hepatic cirrhosis in infants associated with renal involvement are almost diagnostic of this entity.
Se presentan 2 casos documentados de lactantes portadores de Tirosinemia tipo I (Hepatorenal). Se describen los hallazgos imagenológicos principales de ella en los órganos blanco: Hígado (Cirrosis Hepática) y riñones (Nefromegalia) y se confrontan con los de la anatomía patológica en un caso. En un lactante, con un cuadro clínico poco claro, el hallazgo imagenológico de cirrosis hepática sumado a un compromiso renal, deben hacer plantear el diagnóstico de tirosinemia.